cmAngio® vs LINQ II Insertable Cardiac Monitor
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to non-invasively assess cardiovascular risk in women by leveraging existing mammography images. This AI software is ideal for identifying Breast Arterial Calcifications (BAC) to provide early insights into cardiovascular health without requiring additional procedures or radiation. It is best suited for integrating proactive cardiovascular risk screening into routine breast imaging workflows.
View cmAngio® →Choose LINQ II Insertable Cardiac Monitor if…
Choose the Medtronic LINQ II Insertable Cardiac Monitor if you need long-term, continuous, and highly accurate monitoring of heart rhythms for the definitive diagnosis of suspected or unexplained arrhythmias. This insertable device is ideal for patients requiring extended cardiac surveillance, offering AI-powered detection and remote management capabilities for comprehensive arrhythmia diagnosis over several years.
View LINQ II Insertable Cardiac Monitor →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Pricing | Paid, out-of-pocket | Enterprise |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Hybrid |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TiecmAngio focuses on seamless integration into existing radiology workflows with quick installation and compatibility with DICOM viewers, providing clear visualization of findings. LINQ II emphasizes patient convenience through a mobile app and home communicator, alongside remote programming for clinicians. Both offer strong usability but cater to different aspects of the healthcare delivery and user experience.
Clinical Value
LINQ II Insertable Cardiac MonitorWhile cmAngio provides valuable non-invasive cardiovascular risk assessment from existing mammograms, LINQ II offers direct, continuous, and highly accurate diagnosis of critical cardiac arrhythmias over an extended period, with advanced AI algorithms and applicability to pediatric patients. LINQ II's direct diagnostic capability for life-threatening conditions provides a more immediate and impactful clinical value.
Pricing & Value
cmAngio®cmAngio mentions 'limited-time offers for no-cost implementation and service,' suggesting a potentially lower barrier to entry or a more flexible pricing model. LINQ II's pricing is explicitly 'enterprise' and 'negotiated,' with no public disclosure or free trial, indicating a likely higher-cost, integrated solution.
Enterprise Readiness
LINQ II Insertable Cardiac MonitorMedtronic, the company behind LINQ II, is a large, established medical device company founded in 1949, with over 1 million patients having received their ICMs worldwide. This demonstrates a significantly higher level of established enterprise integration, global reach, and proven operational maturity compared to cmAngio.
Innovation
LINQ II Insertable Cardiac MonitorcmAngio innovates by repurposing existing mammography data with AI to provide novel cardiovascular risk insights. However, LINQ II demonstrates more profound innovation in its core technology, featuring advanced AI algorithms for enhanced diagnostic accuracy, remote programming capabilities for an implanted device, extended monitoring duration, and a pediatric indication.
Support & Docs
LINQ II Insertable Cardiac MonitorMedtronic provides comprehensive support for LINQ II, including dedicated patient and technical service phone lines, detailed patient manuals, and clinician manuals. CureMetrix's cmAngio documentation mentions an 'Operator's Manual' but lacks readily accessible direct support contacts or a dedicated support portal in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | LINQ II Insertable Cardiac Monitor |
|---|---|---|
| Name | cmAngiou00ae | LINQ II Insertable Cardiac Monitor |
| Company | CureMetrix | Medtronic |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | An advanced, AI-powered insertable cardiac monitor providing long-term, continuous heart rhythm monitoring with remote programming and enhanced accuracy for diagnosing arrhythmias. |
| Key Features | AI-based detection of Breast Arterial Calcifications (BAC), Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams, Provides visualization of BAC location on a scorecard, Enables BAC identification and reporting without additional radiation or procedures, Compatible with any DICOM-compliant viewer, Adjustable operating point to meet clinical goals, Quick and easy installation (less than an hour), Cybersecure and HIPAA-compliant | AccuRhythmu2122 AI algorithms for enhanced accuracy, Remote programming capability, Up to 4.5 years of continuous monitoring, MRI compatibility (1.5 and 3.0T), MyCareLink Heartu2122 mobile app for data transmission, MyCareLink Relayu2122 home communicator option, Innovative PVC detection algorithm, Pediatric indication (ages 2+) |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and LINQ II Insertable Cardiac Monitor.